Identification of differentially expressed profiles of lncRNAs and mRNAs in ER-negative and HER-2 positive breast cancer

Abstract

<b>Introduction</b>: Breast cancer is one of the most common malignant tumors in the United States. However, the molecular mechanism involved in the progression of breast cancer has remained unclear. Long non-coding RNAs (lncRNA) have been reported as key regulators in the progression and metastasis of cancer.<br /> <b>Material and methods</b>: In this study, we identified significantly differentially expressed mRNAs and lncRNAs in breast cancer using the GSE70947 dataset. Gene ontology (GO) and KEGG pathway was used to explore the key roles of differentially expressed lncRNAs in breast cancer. The dysregulated lncRNAs and mRNAs expression profiles in HER2-positive and ER-negative breast cancer were also analyzed in this study.<br /> <b>Results</b>: Our results showed that PVT1, LOC145837, FLJ40504 and FLJ45983 were significantly decreased in HER2-positive and ER-negative breast cancers. We also constructed the PVT1, LOC145837, FLJ40504 and FLJ45983 mediated cRNA networks in HER2-positive and ER-negative breast cancers. Moreover, using the Betastasis dataset, we found that high PVT1 expression levels were associated with a lower survival rate in breast cancer patients.<br /> <b>Conclusions</b>: These results elucidate the functions of lncRNAs and provide useful information for exploring therapeutic candidate targets and new molecular biomarkers for ER-negative and HER-2 enriched subtype breast cancer.